PRESS RELEASES More events are coming soon. Keyword Search Year: 20232022202120202019201820172016201520142013 05/04/22 Summary Toggle TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022 Printer Friendly PDF Version 04/19/22 Summary Toggle TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K. Printer Friendly PDF Version 03/23/22 Summary Toggle TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference Printer Friendly PDF Version 03/15/22 Summary Toggle TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update Printer Friendly PDF Version 03/11/22 Summary Toggle TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference Printer Friendly PDF Version 03/10/22 Summary Toggle TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol Printer Friendly PDF Version 03/04/22 Summary Toggle TRACON to Report Fourth Quarter and Full Year 2021 Financial Results and Corporate Update on March 15, 2022 Printer Friendly PDF Version 02/02/22 Summary Toggle TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute Printer Friendly PDF Version 01/05/22 Summary Toggle TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Printer Friendly PDF Version 12/27/21 Summary Toggle TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial Printer Friendly PDF Version Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
